Mathurin Fumery, Benedicte Caron, Xavier Hébuterne, Romain Altwegg, Xavier Roblin, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Catherine Le Berre, Lucas Guillo, Amélie Biron, Ludovic Caillo, Anthony Buisson, Stephane Nancey, Mathieu Uzzan, Lucine Vuitton, Cyrielle Gilletta, Sophie Geyl, Antoine Blain, Julien Kirchgesner, Philippe Ah-Soune, Nicolas Duveau, Mathias Vidon, Vered Abitbol, Thierry Paupard, My-Linh Tran-Minh, Antoine Defrance, Laurent Peyrin-Biroulet
INTRODUCTION: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with CD. PATIENTS AND METHODS: From May 2021 to August 2023, all consecutive CD patients treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index (HBI) <5) at 52 weeks. RESULTS: Of the 174 patients included, 99%, 93%, and 96% had been previously exposed to anti-TNF, vedolizumab, and ustekinumab, respectively...
May 8, 2024: Clinical Gastroenterology and Hepatology